The trial compared Moderna's MRNA-4157/V940 vaccine given alongside Merck & Co's cancer immunotherapy Keytruda (pembrolizumab) to Keytruda alone in patients with the skin cancer melanoma.
The Cambridge, Massachusetts-based biotech's personalized cancer vaccine mRNA-4157, developed with Merck (MRK), is currently in late-stage development targeting patients with skin cancer melanoma.
The two partners have presented updated results from the phase 2b KEYNOTE-942 trial of the mRNA-4157 vaccine, given in combination with Merck’s PD-1 inhibitor Keytruda (pembrolizumab ...
Melanoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or ...
Some of the key cancer vaccines in the pipeline include IO102-IO103, mRNA-4157 (V940) + KEYTRUDA, CAN-2409, Nelipepimut-S + Cemiplimab, PDS0101 + Pembrolizumab, PDC*lung01, LB-LR1109, RUTI ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results